Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy?

Annals of Thoracic Surgery

Volumn 85, Issue 2, 2008, Pages 365-367

  Huang, James ^a   Riely, Gregory J ^a   Rosenzweig, Kenneth E ^a   Rusch, Valerie W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; ETOPOSIDE; IMATINIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; HUMAN; METASTASIS; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL RATE; THORACOTOMY; THYMOMA; TREATMENT INDICATION; TREATMENT OUTCOME; UPREGULATION;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; REVIEW LITERATURE AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYMECTOMY; THYMOMA; THYMUS NEOPLASMS;

EID: 38349087555     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.10.098     Document Type: Editorial

References (27)

1. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981) 2485-2492
2. Wright C.D., Wain J.C., Wong D.R., et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health organization histology, and size. J Thorac Cardiovasc Surg 130 (2005) 1413-1421
3. Wright C.D., Choi N.C., Wain J.C., Mathisen D.J., Lynch T.J., and Fidias P. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 85 (2008) 385-389
4. Rea F., Sartori F., Loy M., et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106 (1993) 543-549
5. Venuta F., Rendina E.A., Longo F., et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76 (2003) 1866-1872
6. Lucchi M., Ambrogi M.C., Duranti L., et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 79 (2005) 1840-1844
7. Bretti S., Berruti A., Loddo C., et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 44 (2004) 69-77
8. Kim E.S., Putnam J.B., Komaki R., et al. Phase II study of multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44 (2004) 369-379
9. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
10. Rusch V.W., Giroux D.J., Kraut M.J., et al. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). J Clin Oncol 25 (2007) 313-318
11. Yagi K., Hirata T., Fukuse T., et al. Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded. Ann Thorac Surg 61 (1996) 521-544
12. Wright C.D. Pleuropneumonectomy for the treatment of Masaoka stage IV thymoma. Ann Thorac Surg 82 (2006) 1234-1239
13. Huang J., Rizk N.P., Travis W.D., et al. Feasbility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 134 (2007) 1477-1484
14. Ruffini E., Mancuso M., Oliaro A., et al. Recurrence of thymoma: analysis of clinicopathologic features, treatment and outcome. J Thorac Cardiovasc Surg 113 (1997) 55-63
15. Regnard J.-F., Magdeleinat P., Dromer C., et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 112 (1996) 367-384
16. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
17. Henley J.D., Koukoulis G.K., and Loehrer Sr. P.J. Epidermal growth factor expression in invasive thymoma. J Cancer Res Clin Oncol 128 (2002) 167-170
18. Palmieri G., Marino M., Salvatore M., et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 12 (2007) 757-761
19. Farina G., Garassino M.C., Gambacorta M., et al. Response of thymoma to cetuximab. Lancet Oncol 8 (2007) 449-450
20. Yamaguchi H., Soda H., Kitazaki T., et al. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 52 (2006) 261-262
21. Henley J.D., Cummings O.W., and Loehrer Sr. P.J. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130 (2004) 222-224
22. Pan C.-C., Chen P.C.-H., and Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202 (2004) 375-381
23. Nakagawa K., Matsuno Y., Kunitoh H., et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128 (2005) 140-144
24. Ströbel P., Hartmann M., Jakob A., et al. Thymic carcinoma with overexpression of mutated KIT and the response to Imatinib. N Engl J Med 350 (2004) 2625-2626
25. Chuah C., Lim T.H., Lim A.S., et al. Dasatanib induces a response in malignant thymoma. J Clin Oncol 24 (2006) e56-e58
26. Rieker R.J., Joos S., Mechtersheimer G., et al. COX-2 upregulation in thymomas and thymic carcinomas. Int J Cancer 119 (2006) 2063-2070
27. Müller-Hermelink H.K., Ströbel P., Zettl A., et al. Combined thymic epithelial tumours. In: Travis W.D., Brambilla E., Müller-Hermelink H.K., and Harris C.C. (Eds). Pathology and genetics: tumours of the lung, pleura, thymus and heart (WHO classification of tumours) (2004), IARC Press, Lyon, France 196-201